China’s National Healthcare Security Administration (NHSA) released its 2025 Healthcare Security Development Statistical Bulletin, revealing that Basic Medical Insurance (BMI) participation reached 1.33 billion people (coverage rate >95%), with fund inflows totaling RMB 3,587.3 billion (USD 520 billion) against expenditures of RMB 3,000.9 billion (USD 440 billion). The 2025 NRDL update added 114 new drugs, bringing total covered medicines to 3,253, while DRG/DIP payment reform now covers >95% of inpatient cases and inter-provincial direct settlement surged 30.17% for outpatient visits, demonstrating sustained universal health coverage expansion and cost control efficiency.
Forward‑Looking Statements This brief contains forward‑looking statements regarding BMI sustainability, NRDL expansion, and payment reform implementation based on NHSA 2025 statistical data. Actual results may differ due to demographic shifts, economic growth variations, and healthcare demand inflation.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
